HERON THERAPEUTICS, INC. /DE/
HRTXNasdaq
$0.47
↓ -1.1%Jul 17 close · end-of-day
Price
1Y↓ -76.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$89.3M
Enterprise Value
$44.5M
P/E
—
P/S
0.6
P/B
9.8
EV/EBITDA
—
PEG
—
FCF Yield
-23.4%
Dividend Yield
—
Revenue (TTM)
$150.7M
Net Income (TTM)
-$30.7M
Free Cash Flow (TTM)
-$20.9M
Gross Margin
71.1%
Operating Margin
-6.9%
Net Margin
-20.4%
ROE
-336.5%
ROIC
—
Debt / Equity
—
Net Cash
$44.8M
Return 1Y
-76.5%
Company profile
Heron Therapeutics, Inc. engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy.
- CEO
- Barry D. Quart
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 300
- Headquarters
- California
- Website
- herontx.com
Management & directors
- Duarte IraEVP, Chief Financial Officer
- Forbes William PEVP, Chief Development Officer
- Hensley Mark EarlChief Operating Officer
- Collard Craig AChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
HRTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$34.7M↓ -10.8%
Diluted EPS-$0.04↓ -500.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $88.6M | $86.3M | $107.7M | $127.0M | $144.3M | $154.9M |
| Gross profit | — | — | $52.8M | $61.9M | $105.6M | $113.6M |
| Operating income | -$228.2M | -$217.8M | -$174.7M | -$110.6M | -$11.5M | -$2.5M |
| Net income | -$227.3M | -$221.0M | -$182.0M | -$111.0M | -$14.0M | -$20.0M |
| Diluted EPS | — | -$2.24 | -$1.67 | -$0.80 | -$0.09 | -$0.12 |
| Operating cash flow | -$184.8M | -$203.4M | -$146.9M | -$58.8M | -$22.5M | -$27.6M |
| Free cash flow | -$191.6M | -$206.4M | -$148.7M | -$60.3M | -$24.2M | -$27.9M |
| Gross margin | — | — | 49.0% | 48.8% | 73.2% | 73.3% |
| Operating margin | -257.4% | -252.3% | -162.2% | -87.1% | -8.0% | -1.6% |
| Net margin | -256.4% | -255.9% | -169.0% | -87.4% | -9.7% | -12.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.0M | $32.8M | $40.8M | $38.9M | $37.2M | $38.2M | $40.6M | $34.7M |
| Gross profit | $25.5M | $23.4M | $30.6M | $30.4M | $27.3M | $26.3M | $29.5M | $24.1M |
| Operating income | -$6.4M | -$4.5M | $4.2M | $3.2M | -$1.6M | -$4.1M | $38,000.00 | -$4.8M |
| Net income | -$9.2M | -$4.8M | $3.2M | $2.6M | -$2.4M | -$17.5M | -$2.8M | -$8.1M |
| Diluted EPS | -$0.06 | -$0.03 | $0.02 | $0.01 | -$0.02 | -$0.10 | -$0.01 | -$0.04 |
| Operating cash flow | -$4.6M | $3.4M | -$11.8M | -$8.9M | -$10.9M | $1.3M | -$9.2M | -$1.5M |
| Free cash flow | — | $2.9M | — | -$9.0M | -$11.1M | $1.3M | -$9.2M | -$1.9M |
| Gross margin | 70.8% | 71.2% | 74.9% | 78.3% | 73.5% | 68.8% | 72.6% | 69.4% |
| Operating margin | -17.9% | -13.6% | 10.2% | 8.1% | -4.4% | -10.7% | 0.1% | -13.7% |
| Net margin | -25.6% | -14.8% | 8.0% | 6.8% | -6.4% | -45.8% | -6.8% | -23.4% |
Company news
Jul 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-16 | Duarte Ira· EVP, Chief Financial Officer | Tax withholding | 3,555 | $0.38 | $1,350.90 | filing |
| 2026-06-16 | Duarte Ira· EVP, Chief Financial Officer | Option exercise | 12,500 | — | — | filing |
| 2026-06-06 | Forbes William P· EVP, Chief Development Officer | Option exercise | 12,500 | — | — | filing |
| 2026-05-06 | Hensley Mark Earl· Chief Operating Officer | Option exercise | 125,000 | — | — | filing |
| 2026-04-30 | Duarte Ira· EVP, Chief Financial Officer | Option exercise | 11,694 | — | — | filing |
| 2026-04-30 | Duarte Ira· EVP, Chief Financial Officer | Option exercise | 13,535 | — | — | filing |
| 2026-04-30 | Collard Craig A· Chief Executive Officer | Option exercise | 34,789 | — | — | filing |
| 2026-04-30 | Collard Craig A· Chief Executive Officer | Option exercise | 50,021 | — | — | filing |
| 2026-04-30 | Hensley Mark Earl· Chief Operating Officer | Option exercise | 11,770 | — | — | filing |
| 2026-04-30 | Forbes William P· EVP, Chief Development Officer | Option exercise | 11,694 | — | — | filing |
| 2026-04-30 | Forbes William P· EVP, Chief Development Officer | Option exercise | 11,770 | — | — | filing |
| 2026-04-19 | Duarte Ira· EVP, Chief Financial Officer | Option exercise | 3,874 | — | — | filing |
| 2026-04-19 | Forbes William P· EVP, Chief Development Officer | Option exercise | 3,874 | — | — | filing |
| 2026-04-19 | Collard Craig A· Chief Executive Officer | Option exercise | 13,797 | — | — | filing |
| 2026-04-03 | Collard Craig A· Chief Executive Officer | Option exercise | 62,500 | — | — | filing |
| 2026-01-31 | Duarte Ira· EVP, Chief Financial Officer | Option exercise | 11,695 | — | — | filing |
| 2026-01-31 | Forbes William P· EVP, Chief Development Officer | Option exercise | 11,695 | — | — | filing |
| 2026-01-31 | Collard Craig A· Chief Executive Officer | Option exercise | 34,789 | — | — | filing |
| 2026-01-30 | Christian Waage | Award | 53,960 | $0.00 | $0.00 | filing |
| 2026-01-30 | Kaseta Michael | Award | 53,960 | $0.00 | $0.00 | filing |
| 2026-01-30 | Johnson Craig A | Award | 53,960 | $0.00 | $0.00 | filing |
| 2026-01-30 | Cusack Thomas | Award | 53,960 | $0.00 | $0.00 | filing |
| 2026-01-30 | Dissanaike Sharmila | Award | 53,960 | $0.00 | $0.00 | filing |
| 2026-01-30 | Morgan Adam | Award | 53,960 | $0.00 | $0.00 | filing |
| 2026-01-19 | Forbes William P· EVP, Chief Development Officer | Option exercise | 3,875 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.